Cargando…
IL-17 and IL-17-producing cells in protection versus pathology
IL-17 cytokine family members have diverse biological functions, promoting protective immunity against many pathogens but also driving inflammatory pathology during infection and autoimmunity. IL-17A and IL-17F are produced by CD4(+) and CD8(+) T cells, γδ T cells, and various innate immune cell pop...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255545/ https://www.ncbi.nlm.nih.gov/pubmed/35790881 http://dx.doi.org/10.1038/s41577-022-00746-9 |
_version_ | 1784740943408136192 |
---|---|
author | Mills, Kingston H. G. |
author_facet | Mills, Kingston H. G. |
author_sort | Mills, Kingston H. G. |
collection | PubMed |
description | IL-17 cytokine family members have diverse biological functions, promoting protective immunity against many pathogens but also driving inflammatory pathology during infection and autoimmunity. IL-17A and IL-17F are produced by CD4(+) and CD8(+) T cells, γδ T cells, and various innate immune cell populations in response to IL-1β and IL-23, and they mediate protective immunity against fungi and bacteria by promoting neutrophil recruitment, antimicrobial peptide production and enhanced barrier function. IL-17-driven inflammation is normally controlled by regulatory T cells and the anti-inflammatory cytokines IL-10, TGFβ and IL-35. However, if dysregulated, IL-17 responses can promote immunopathology in the context of infection or autoimmunity. Moreover, IL-17 has been implicated in the pathogenesis of many other disorders with an inflammatory basis, including cardiovascular and neurological diseases. Consequently, the IL-17 pathway is now a key drug target in many autoimmune and chronic inflammatory disorders; therapeutic monoclonal antibodies targeting IL-17A, both IL-17A and IL-17F, the IL-17 receptor, or IL-23 are highly effective in some of these diseases. However, new approaches are needed to specifically regulate IL-17-mediated immunopathology in chronic inflammation and autoimmunity without compromising protective immunity to infection. |
format | Online Article Text |
id | pubmed-9255545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-92555452022-07-06 IL-17 and IL-17-producing cells in protection versus pathology Mills, Kingston H. G. Nat Rev Immunol Review Article IL-17 cytokine family members have diverse biological functions, promoting protective immunity against many pathogens but also driving inflammatory pathology during infection and autoimmunity. IL-17A and IL-17F are produced by CD4(+) and CD8(+) T cells, γδ T cells, and various innate immune cell populations in response to IL-1β and IL-23, and they mediate protective immunity against fungi and bacteria by promoting neutrophil recruitment, antimicrobial peptide production and enhanced barrier function. IL-17-driven inflammation is normally controlled by regulatory T cells and the anti-inflammatory cytokines IL-10, TGFβ and IL-35. However, if dysregulated, IL-17 responses can promote immunopathology in the context of infection or autoimmunity. Moreover, IL-17 has been implicated in the pathogenesis of many other disorders with an inflammatory basis, including cardiovascular and neurological diseases. Consequently, the IL-17 pathway is now a key drug target in many autoimmune and chronic inflammatory disorders; therapeutic monoclonal antibodies targeting IL-17A, both IL-17A and IL-17F, the IL-17 receptor, or IL-23 are highly effective in some of these diseases. However, new approaches are needed to specifically regulate IL-17-mediated immunopathology in chronic inflammation and autoimmunity without compromising protective immunity to infection. Nature Publishing Group UK 2022-07-05 2023 /pmc/articles/PMC9255545/ /pubmed/35790881 http://dx.doi.org/10.1038/s41577-022-00746-9 Text en © Springer Nature Limited 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article Mills, Kingston H. G. IL-17 and IL-17-producing cells in protection versus pathology |
title | IL-17 and IL-17-producing cells in protection versus pathology |
title_full | IL-17 and IL-17-producing cells in protection versus pathology |
title_fullStr | IL-17 and IL-17-producing cells in protection versus pathology |
title_full_unstemmed | IL-17 and IL-17-producing cells in protection versus pathology |
title_short | IL-17 and IL-17-producing cells in protection versus pathology |
title_sort | il-17 and il-17-producing cells in protection versus pathology |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255545/ https://www.ncbi.nlm.nih.gov/pubmed/35790881 http://dx.doi.org/10.1038/s41577-022-00746-9 |
work_keys_str_mv | AT millskingstonhg il17andil17producingcellsinprotectionversuspathology |